DaVita (NYSE:DVA) Announces Quarterly Earnings Results, Beats Expectations By $0.54 EPS

DaVita (NYSE:DVA) posted its quarterly earnings data on Tuesday. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54, Zacks reports. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The business’s revenue was up 6.0% on a year-over-year basis. DaVita updated its FY 2026 guidance to 14.100-15.200 EPS.

Here are the key takeaways from DaVita’s conference call:

• DaVita raised and narrowed its 2026 guidance — adjusted operating income to $2.15B–$2.25B and adjusted EPS to $14.10–$15.20 — attributing the increase mainly to higher volume and lower patient-care costs.
• Treatment volume guidance was lifted to +25–50 bps (≈+50–75 bps normalized treatments per day) driven by better-than-forecast mortality and patient transfers from Fresenius clinic closures.
• Q1 results beat expectations with adjusted operating income of $482M, adjusted EPS of $2.87, and free cash flow of $140M; the company repurchased ~5M shares and ended the quarter with leverage at 3.34x EBITDA.
• Management is investing in data, a proprietary EMR, and AI applications (e.g., Schedule Hub) to boost productivity and clinical outcomes, but benefits are early and contributed to a ~13% increase in G&A versus prior year.
• ACA open-enrollment is trending slightly more favorable than the prior ~$40M headwind estimate, but a shift toward lower-tier bronze plans could raise patient out-of-pocket costs and modestly pressure revenue per treatment.

DaVita Price Performance

Shares of NYSE DVA traded up $31.07 during trading on Wednesday, reaching $188.11. 1,781,820 shares of the stock traded hands, compared to its average volume of 993,276. DaVita has a 52-week low of $101.00 and a 52-week high of $190.26. The company has a 50-day moving average of $151.30 and a 200-day moving average of $131.73. The stock has a market capitalization of $12.57 billion, a P/E ratio of 18.99, a price-to-earnings-growth ratio of 0.54 and a beta of 0.84.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DVA. Corient Private Wealth LLC lifted its position in shares of DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of DaVita by 109.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after buying an additional 289,725 shares during the last quarter. Man Group plc lifted its position in shares of DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after buying an additional 269,081 shares during the last quarter. Voloridge Investment Management LLC lifted its position in shares of DaVita by 2,905.7% during the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock valued at $30,324,000 after buying an additional 220,628 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of DaVita by 202.8% during the 4th quarter. Barclays PLC now owns 288,320 shares of the company’s stock valued at $32,756,000 after buying an additional 193,113 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the topic of several research analyst reports. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $126.00 to $220.00 in a research report on Wednesday. UBS Group boosted their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Barclays boosted their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $166.50.

DaVita News Roundup

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 results beat estimates — Adjusted EPS of $2.87 and revenue of ~$3.42B topped consensus, showing year‑over‑year earnings growth and improved operating performance. DaVita Inc. 1st Quarter 2026 Results
• Positive Sentiment: Company raised FY‑2026 guidance — DaVita lifted its adjusted EPS and operating income ranges, which reduces execution risk for the year and supports multiple expansion. DaVita lifts annual profit forecast on strong demand for dialysis services
• Positive Sentiment: Share repurchases continued — Management repurchased stock during the quarter and disclosed additional buybacks through May 5, which supports EPS and signals confidence from the board. DaVita shares jump as Q1 results beat expectations and full-year outlook rises
• Positive Sentiment: Analyst activity turned constructive — At least one firm (Deutsche Bank) issued a Buy / higher target on May 6, which can amplify momentum after the beat-and-raise. DaVita shares jump as Q1 results beat expectations and full-year outlook rises
• Neutral Sentiment: Unusual options flow — Call purchases spiked (~3,984 calls, ~140% above typical), reflecting speculative or hedged bullish positioning ahead of/after the release; could amplify intraday moves but doesn’t change fundamentals.
• Neutral Sentiment: Earnings call transcript available for detail — Investors can review the May 5 transcript for color on reimbursement, cost trends, and-capex. DaVita Inc. (DVA) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Significant insider/institutional selling noted — Large sales (including Berkshire Hathaway dispositions) and net reductions by some managers were reported in recent filings; could cap upside if selling persists. DaVita shares jump as Q1 results beat expectations and full-year outlook rises

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.